These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Molecular modelling approaches for cystic fibrosis transmembrane conductance regulator studies. Odolczyk N; Zielenkiewicz P Int J Biochem Cell Biol; 2014 Jul; 52():39-46. PubMed ID: 24735712 [TBL] [Abstract][Full Text] [Related]
30. The implications of CFTR structural studies for cystic fibrosis drug development. Callebaut I; Hoffmann B; Mornon JP Curr Opin Pharmacol; 2017 Jun; 34():112-118. PubMed ID: 29096277 [TBL] [Abstract][Full Text] [Related]
31. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis. Roomans GM Am J Respir Med; 2003; 2(5):413-31. PubMed ID: 14719993 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function. Arora K; Naren AP Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081 [TBL] [Abstract][Full Text] [Related]
33. Ion Channel Modulators in Cystic Fibrosis. Gentzsch M; Mall MA Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923 [TBL] [Abstract][Full Text] [Related]
34. In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library. Orro A; Uggeri M; Rusnati M; Urbinati C; Pedemonte N; Pesce E; Moscatelli M; Padoan R; Cichero E; Fossa P; D'Ursi P Eur J Med Chem; 2021 Mar; 213():113186. PubMed ID: 33472120 [TBL] [Abstract][Full Text] [Related]
35. Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis. Wang X; Liu B; Searle X; Yeung C; Bogdan A; Greszler S; Singh A; Fan Y; Swensen AM; Vortherms T; Balut C; Jia Y; Desino K; Gao W; Yong H; Tse C; Kym P J Med Chem; 2018 Feb; 61(4):1436-1449. PubMed ID: 29251932 [TBL] [Abstract][Full Text] [Related]
36. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
39. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]